Compare Conagra Brands Inc (CAG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Conagra Brands Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Conagra Brands Inc trades at $15.02 (market cap $7.14B), while State Street SPDR S&P Biotech ETF trades at $159.02. The key difference: Conagra Brands Inc pays a 8.2% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Conagra Brands Inc nearer its low. Which is the better fit depends on your goals.
| CAG | XBI | |
|---|---|---|
Market Cap | $7.14B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $20.02 | $164.28 |
52-Week Low | $12.58 | $86.92 |
Enterprise Value | $14.20B | — |
Dividend Yield | 8.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Conagra Brands (CAG) trades at $14.985, up 1.39% with neutral technical signals. The company shows mixed fundamentals with a P/E of 10.06 and P/S of 0.63 suggesting undervaluation, but negative net income margin (-16.99%) and ROE (-25.06%) reflect profitability challenges. Recent earnings show two beats and one miss in the last four quarters, with Q3 2026 results pending. The company recently cut its dividend by 50% to prioritize debt reduction and operational improvements under new CEO John Brase.
CAG presents a turnaround story with attractive valuation metrics but faces significant headwinds including declining sales, margin pressure, and high debt levels. Analyst consensus is cautious with 62.5% hold ratings and a $13.67 price target below current levels. The dividend cut provides financial flexibility but signals ongoing challenges. Investors should weigh the discounted valuation against persistent operational pressures and weak growth outlook.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
